Nomograms Predict Outcomes After 177Lu-PSMA Therapy in Men With Metastatic Castration–Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nomograms to Predict Outcomes After 177Lu-PSMA Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: An International, Multicentre, Retrospective Study
Lancet Oncol 2021 Jul 08;[EPub Ahead of Print], A Gafita, J Calais, TR Grogan, B Hadaschik, H Wang, M Weber, S Sandhu, C Kratochwil, R Esfandiari, R Tauber, A Zeldin, H Rathke, WR Armstrong, A Robertson, P Thin, C D'Alessandria, MB Rettig, ES Delpassand, U Haberkorn, D Elashoff, K Herrmann, J Czernin, MS Hofman, WP Fendler, M EiberFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.